Defactinib
Avmapki Fakzynja Co-pack (defactinib) is a small molecule pharmaceutical. Defactinib was first approved as Avmapki fakzynja co-pack (copackaged) on 2025-05-08.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Combinations
Avmapki fakzynja co-pack
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| avmapki fakzynja co-pack | New Drug Application | 2025-05-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 6 | — | — | — | 8 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 4 | — | — | — | 7 |
| Neoplasms | D009369 | — | C80 | 6 | 3 | — | — | — | 7 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 4 | — | — | — | 6 |
| Mesothelioma | D008654 | — | C45 | 3 | 3 | — | — | — | 5 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 4 | — | — | — | 5 |
| Malignant mesothelioma | D000086002 | — | — | 2 | 2 | — | — | — | 4 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 2 | — | — | — | 3 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 1 | — | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | — | 2 | — | — | — | 2 |
Show 31 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | — | — | 1 | — | — | — | — | 1 |
| Plexiform neurofibroma | D018318 | EFO_0000658 | — | 1 | — | — | — | — | 1 |
| Nervous system neoplasms | D009423 | — | — | 1 | — | — | — | — | 1 |
| Optic nerve glioma | D020339 | — | — | 1 | — | — | — | — | 1 |
| Neurofibromatoses | D017253 | — | Q85.00 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Defactinib |
| INN | defactinib |
| Description | Defactinib (INN, codenamed VS-6063) is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 1073154-85-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3137331 |
| ChEBI ID | — |
| PubChem CID | 25117126 |
| DrugBank | DB12282 |
| UNII ID | 53O87HA2QU (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,129 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
363 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use